RAC
Race Oncology Ltd
π¦πΊ ASX
𧬠BIOTECHNOLOGY
π Overview
π Performance
π΅ Cost
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
+ 187.14%
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
23
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Race Oncology Ltd. is a clinical stage biotechnology company, which engages in the discovery and development of a novel approach to cancer treatment and cardio protection. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. The firm is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. Its lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. The company is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations. The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.
π Performance
Price History
+625.00%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$1.45
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in RAC
23
π Total Capital Earnings
$13K
π Average investment frequency
36 weeks
π΅ Average investment amount
$2,759
β° Last time a customer invested in RAC
4 days
RAC investor breakdown
π΅ Income of investors
More than 200k
16%
150k - 200k
100k - 150k
6%
50k - 100k
31%
Less than 50k
31%
πΆ Age of investors
18 - 25
26 - 34
13%
35 - 90
83%
π Legal gender of investors
Female
26%
Male
74%
Pearlers who invest in RAC also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
4.43%
π Share price
$104.33 AUD
𧱠MATERIALS
β³οΈ DIVERSIFIED
πΈ FINANCIALS
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
13.28%
π Share price
$134.96 AUD
π GLOBAL
β³οΈ DIVERSIFIED
π€ TECHNOLOGY
π HIGH PRICE GROWTH
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
4.09%
π Share price
$68.57 AUD
π GLOBAL
β³οΈ DIVERSIFIED
ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).
π Performance (5Yr p.a)
12.72%
π Share price
$82.30 AUD
π GLOBAL
ποΈ CONSUMER
π INDUSTRIALS
π€ TECHNOLOGY
π HIGH PRICE GROWTH
Want more shares? Try these...
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The company has a pipeline of differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the universities and institutes around the world. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumor cancers including lung, pancreas and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.
π Share price
$0.03 AUD
𧬠BIOTECHNOLOGY